文献类型：期刊文献

英文题名：Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

作者：Danso, Felix[1,2];Abd El-Aty, A. M.[3,4];Amoah, Kwaku[5];Ju, Xianghong[1,2,6]

机构：[1]Guangdong Ocean Univ, Coll Coastal Agr Sci, Dept Vet Med, Zhanjiang, Peoples R China;[2]Guangdong Ocean Univ, Marine Med Res & Dev Ctr, Shenzhen Inst, Shenzhen, Peoples R China;[3]Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza, Egypt;[4]Ataturk Univ, Med Fac, Dept Med Pharmacol, Erzurum, Turkiye;[5]Guangdong Prov Key Lab Aquat Anim Dis Control & Hl, Zhanjiang, Peoples R China;[6]Zhanjiang City Key Lab Anim Dis Prevent & Control, Zhanjiang, Peoples R China

年份：2026

外文期刊名：FOOD SAFETY AND HEALTH

收录：ESCI(收录号：WOS:001746784800001)、WOS

基金：This study was supported by the National Natural Science Foundation of China (32273077); Guangdong Major Project of Basic and Applied Basic Research (No. 2023B0303000014); the Innovation Team Project of Guangdong Provincial Department of Education (2022KCXTD014); the Guangdong Postgraduate Education Innovation Project (040510052201); and the National Natural Science Foundation of Shenzhen (JCYJ20250604174202003); and the Program for Scientific Research Start-up Funds of Guangdong Ocean University (060302022310).

语种：英文

外文关键词：Crohn's disease (CD); inflammatory bowel disease (IBD); mechanisms; microbiota; nanoparticles; natural polysaccharides (NPs); ulcerative colitis (UC)

外文摘要：Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a recurrent gastrointestinal condition with a rising global prevalence. Current treatments, such as anti-inflammatory drugs and biologics, are often limited by severe side effects and drug resistance, driving the search for safer alternatives. Natural polysaccharides (NPs) and their metabolites, particularly short-chain fatty acids (SCFAs), have garnered significant interest because of their immunomodulatory, antioxidative, and microbiota-modulating properties, positioning them as promising bioactive agents for IBD management. This review critically examines the structure-activity relationships of NPs and advanced delivery strategies, including nanoformulations, that increase their bioavailability and targeting ability. It also provides a comprehensive evaluation of the existing evidence, an in-depth analysis of safety profiles, and a critical discussion of clinical translation prospects, addressing complexities in regulatory frameworks. By integrating recent molecular insights with translational challenges, this review aims to inform clinical practice and temper premature expectations, offering a balanced perspective on the journey of NPs from the bench to the bedside.